| Drug Name |
Halobetasol |
| Drug ID |
BADD_D01051 |
| Description |
Ulobetasol is a highly potent corticosteroid.[A215597] It is structurally related to [clobetasol].[A215597] Due to its high potency, it is mainly prescribed in the treatment of severe plaque psoriasis and corticosteroid responsive dermatoses.[L15047,L15052,L15102]
Ulobetasol was granted FDA approval on 17 December 1990.[L15047] |
| Indications and Usage |
Ulobetasol cream and ointment are indicated in the treatment of inflammatory and pruritic corticosteroid responsive dermatoses.[L15047] Ulobetasol lotion is indicated in the treatment of plaque psoriasis.[L15052] |
| Marketing Status |
approved |
| ATC Code |
D07AC21 |
| DrugBank ID |
DB00596
|
| KEGG ID |
D08660
|
| MeSH ID |
C064466
|
| PubChem ID |
5311167
|
| TTD Drug ID |
D00XPC
|
| NDC Product Code |
Not Available |
| UNII |
9P6159HM7T
|
| Synonyms |
halobetasol | ulobetasol | Ultravate | halobetasol propionate | 6 alpha-fluoroclobetasol 17-propionate | 6-fluoroclobetasol 17-propionate | CGP 14 458 | CGP-14458 | CGP 14458 |
